Replies to post #200377 on Avid Bioservices Inc (CDMO)

[pphmtoolong]

dia76ca, given what appears to be a rapidly moving and most likely successful Phase III trial, I too am looking eagerly forward to next year.

I know we have heard it and said it before, but 2015 will be different. Bavituximab has a strong scientific pedigree. The lab and clinical results line up well. Despite the screw up by the Fargo contractor, the Phase II trial produced very promising data. The Sunrise trial closely replicates the Phase II trial.

We have every reason to expect success. Of course, there is no guarantee of Sunrise success, but I like our chances. If "the street" or anyone else has a different opinion, I don't care. We know this story better than they do.

GLTA, Paul